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HIV-1, Vpr and the cell cycle
Michael Emerman
The human immunodeficiency virus 1 (HIV-1) is a
complex retrovirus with more genes than most
retroviruses. One of these extra genes codes for a
protein called Vpr, which has recently been shown to
prevent activation of the mitotic cyclin-dependent kinase
and thereby prevent infected cells from undergoing
mitosis and proliferating. Vpr also plays an important
role in another property of HIV-1 that is unusual for a
retrovirus — its ability to enter the nucleus of a
nondividing cell. Understanding the interactions between
HIV-1 and the cell cycle should lead to new insights into
both viral pathogenesis and basic cell biology.
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Introduction
Human immunodeficiency virus 1 (HIV-1), the causative
agent of acquired immunodeficiency syndrome (AIDS), is a
member of the lentivirus class of retroviruses. Retroviruses
are RNA viruses that use a viral enzyme, reverse transcrip-
tase, to copy their genome into DNA which is then effi-
ciently integrated into the host-cell genome. HIV-1
primarily infects activated CD4 T cells and terminally
differentiated cells of the macrophage lineage. Progressive
depletion of CD4 T cells is the defining feature of the
immunodeficiency, whereas infection of brain macrophages
and/or microglial cells is responsible for AIDS dementia [1]
and infection of Langerhans cells in the macrophage
lineage may be important for viral transmission [2–4].
Our understanding of HIV-1 pathogenesis has changed
enormously in the last two to three years. Until recently, it
was thought that the long period of latency between the
time of infection and the onset of AIDS was associated
with latency of the virus within infected cells. Now,
however, we know that large amounts of virus are pro-
duced in the lymph nodes at all times [5,6]. Moreover,
recent studies have shown that over 99 % of the virus in
the periphery is produced by cells with a half-life of less
than two days [7–9]. About 2 × 109 infected cells are killed
and about the same number are replenished every day in
an HIV-1-infected individual [7]. There is currently some
debate about whether the replenishment of T cells in the
periphery is due to regeneration or to redistribution [10].
Nonetheless, the overall picture is one in which virally
infected cells are rapidly eliminated, but not before
enough new virus is produced to sustain new rounds of
infection. One hypothesis for HIV-1 pathogenesis is that,
in the course of the disease, higher levels of virus lead to
higher levels of cell death which eventually outrun the
replenishment of T cells.
A second class of retroviruses, called oncoviruses because
they are often oncogenic, differ from HIV-1 and the
lentiviruses both in their genome structure and in their
effects on infected hosts. HIV-1 is a complex retrovirus
with a genome that includes nine genes (Fig. 1). With the
exception of the human T-cell leukemia viruses, most
oncoviruses, in contrast, are simple and have only three
genes; they establish chronic infections in which the inte-
grated provirus replicates with the host-cell genome as a
permanent part of a chromosome, all the while continuing
to produce virus. Indeed, vestiges of ancient integrations
of oncoviruses into the germline genome, called endoge-
nous viruses, mark the genomes of nearly all vertebrate
species. In contrast to HIV-1, which causes destruction of
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the productively infected host cells within a short time of
infection, most oncogenic retroviruses have no deleterious
effects on the growth or function of their host cell.
Given the different relationships HIV-1 and oncoviruses
have with their host cells, it is not surprising to find that
the interaction of HIV-1 with the host cell cycle is unlike
that of many other retroviruses. Recent results, which I
shall review here, show that a protein encoded by the
HIV-1 genome and called Vpr — for viral protein R
[11,12] — plays an important part in two unusual aspects
of the interaction between HIV-1 and the host cell cycle.
Vpr prevents infected cells from proliferating, by interfer-
ing with normal cell-cycle control, and it collaborates with
the matrix protein (MA) to enable HIV-1 to enter the
nucleus of a nondividing cells. Thus, the replication of
HIV-1 and ultimately its pathogenesis are intrinsically tied
to cell-cycle control. 
Vpr and cell-cycle control
Vpr is a 96 amino-acid (14 kDa) protein, encoded by a
small open-reading frame, vpr, which overlaps the vif and
tat genes at the 5′ and 3′ ends, respectively (Fig. 1).
Among different HIV-1 isolates, vpr is one of the most
conserved genes [13]. T cells infected in culture with an
HIV-1 isolate that contains an intact vpr gene do not grow
and eventually die [14–16]. Although it is possible to
derive a culture of T cells that are chronically infected
with HIV-1, in nearly all cases the virus particles pro-
duced contain mutations in vpr [15,17]. For example, the
H9/HIVIIIb strain from Robert Gallo’s laboratory, which
has been in culture for over a decade, contains a
frameshift mutation that truncates the predicted Vpr
protein and renders it nonfunctional [13]. Cells expressing
normal Vpr, from the complete HIV-1 genome or alone
from an expression plasmid carrying vpr, do not prolifer-
ate but accumulate in the G2 phase of the cell cycle
[15,18–21], before breakdown of the nuclear envelope and
chromatin condensation [19,21]. Vpr thus prevents cells
from passing into mitosis. 
Vpr prevents mitosis in human and primate cells from a
variety of tissues, as well as in infected T cells [15,18–21],
but not in at least one mouse cell line [19]. It is cytostatic
rather than cytotoxic, because T cells that express Vpr can
be arrested in G2 for several days [21]; however, cells
respond in different ways to this cytostatic effect. Some
tumor cell lines differentiate as a result of the block to cell
proliferation [22], whereas others reinitiate DNA synthesis
leading to polyploidy [21]. The modest enhancement by
Vpr of transcription driven by regulatory sequences in the
viral long-terminal repeat (LTR) [23] may also be a result
of cell-cycle arrest in G2, which would explain why Vpr
can activate latent proviruses [24]. Eventually, T cells
expressing Vpr die by apoptosis (I. Chen, personal com-
munication). The consequences of Vpr expression are
thus multifaceted, and might be expected to have
complex effects on the host.
Passage of cells from G2 into mitosis is controlled by the
mitotic cyclin-dependent kinase (Cdk) complex, a
complex of the regulatory subunit cyclin B and the
catalytic subunit p34cdc2 (Fig. 2; reviewed in [25]). The
protein kinase activity of p34cdc2 depends on association
with cyclin B, which is destroyed during mitosis and syn-
thesized anew in late S phase and G2 . Phosphorylation of
p34cdc2 on residue Thr161 by cyclin-activating kinase
(CAK) is also necessary for mitotic Cdk activity. Although
mitotic Cdk is produced, and phosphorylated by CAK, in
early G2, the protein kinase wee1 prevents its premature
activation by phosphorylating p34cdc2 on residues Thr14
and Tyr15; dephosphorylation of Thr14/Tyr15 by the
protein phosphatase CDC25C eventually activates
cyclin B–p34cdc2, allowing progression to mitosis. 
Figure 1
Genome organization of HIV-1 and SIV. Open
reading frames that encode proteins which
are efficiently incorporated into virions are in
orange; those encoding regulatory proteins
are in blue; and those encoding other auxiliary
proteins are in green. The different vertical
positions denote different reading frames. The
long terminal repeats (LTRs), shaded grey,
contain sequences necessary for
transcriptional initiation and termination,
integration and binding the viral transactivator
Tat. The genomes of oncogenic retroviruses
have only three genes: gag, pol and env.
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Cells that express Vpr have very low or undetectable
levels of cyclin B–p34cdc2 kinase activity, although both
cyclin B and p34cdc2 proteins are present [18,20,21]. The
cyclin B–p34cdc2 kinase is inactive because of phos-
phorylation on Thr14 and Tyr15 [18–21]. It is unlikely
that Vpr blocks the activity of the cyclin B–p34cdc2 kinase
directly, because expression of a mutant p34cdc2 that
cannot be inactivated by hyperphosphorylation, because
of Thr14/Tyr15 mutation, overcomes the Vpr-induced G2
block [20]. Moreover, Vpr does not bind to cyclin B or
p34cdc2 [18], and forced activation of cyclin B–p34cdc2 by
treatment of cells with the phosphatase inhibitor okadaic
acid overcomes the Vpr-induced G2 block [19]. Vpr there-
fore prevents cells from entering mitosis by interfering
with a stage of the cell cycle that is upstream of
cyclin B–p34cdc2 activation by dephosphorylation. 
The wee1 kinase and CDC25C phosphatase that control
the kinase activity of cyclin B–p34cdc2 are themselves con-
trolled by phosphorylation. In cells that express Vpr,
CDC25C is in its inactive, hypophosphorylated state [18],
and wee1 is in its active hypophosphorylated state (W.
Greene, personal communication). It is likely, therefore,
that Vpr acts upstream of these enzymes to affect their
coordinate regulation (Fig. 2). Activation of the DNA
damage-induced checkpoint control in G2 would also
have these effects, but it is unlikely that Vpr causes DNA
damage because the arrest in G2 by Vpr is unaffected by
the presence or absence of the p53 and ataxia telangecta-
sia (AT) proteins, which mediate a checkpoint that arrests
the cell cycle in response to damaged DNA, and is qualita-
tively different from the DNA-damage checkpoint control
in its response to methylxanthines [21]. These results do
not, however, rule out the possibility that Vpr acts down-
stream of checkpoint controls on either DNA damage or
DNA synthesis (Fig. 2). In addition, because of its
involvement with protein import into the nucleus (see
below), it is possible that Vpr interferes with the transition
from G2 to mitosis by interfering with the intracellular
localization of a rate-limiting protein during G2. 
Various cellular proteins bind to Vpr, but none fully
explains Vpr’s biological effects. The transcription factor
Sp1 [26] and a 41 kDa cytosolic protein that coprecipitates
with the glucocorticoid receptor [27] were shown to bind
Vpr by direct binding assays. The cellular protein uracil
DNA-glycosylase (UNG), which initiates removal of uracil
from DNA that has been formed by incorporation of dUTP
or by deamination of cytosine, was found to bind to Vpr
[28]. However, Saccharomyces cerevisiae cells that lack UNG
are viable, and no cell-cycle defect is caused by either
under- or over-expression of UNG [29,30], so UNG has no
obvious involvement in the cell cycle. Lastly, an intriguing
interaction has been found between the 65 kDa regulatory
subunit of the enzyme protein phosphatase 2A (PP2A) and
Vpr (W. Greene, personal communication). PP2A is a
protein serine/threonine phosphatase that plays many roles
in cell metabolism. Among these roles is the regulation of
the transition from G2 to mitosis through the dephospho-
rylation of CDC25C and wee1 [31]. Interaction of Vpr with
PP2A could, therefore, play a role in causing constitutive
activation of wee1 and inactivation of CDC25C.
A major reason to remain cautious about data implicating
various Vpr binding partners is simply that there are so
many of them. In addition to the proteins already men-
tioned, direct binding, yeast two-hybrid and genetic
experiments have also indicated that Vpr binds to itself
(R. Benarous, personal communication) and to at least
three places on the HIV-1 Gag polyprotein [32–34]. It will
Figure 2
Points at which Vpr might interact with the
cell cycle to effect a G2-phase cell-cycle
arrest. Arrowheads indicate activation and
T-heads indicate inhibition; solid lines
indicate direct interaction and dashed lines
indicate indirect interaction. As explained in
the text, wee1 is a kinase that inhibits
cyclin B–p34cdc2 activity, and CDC25C is a
phosphatase that activates it. Vpr probably
acts upstream of CDC25C and wee1 by
indirectly causing inhibition of CDC25C and
activation of wee1. PP2A has been
implicated in the phosphorylation control of
CDC25C and wee1 (see text). It is also
possible that Vpr acts downstream of a G2
checkpoint. 
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be a challenge to determine which are the biologically
relevant interactions. Because the proliferation of both
S. cerevisiae [35] and Schizosaccharomyces pombe [36] cells are
also inhibited by Vpr, studies in these genetically tractable
organisms may help determine the roles that interaction of
Vpr with other host-cell proteins play in cell-cycle control.
S. pombe appears the better model system, because Vpr
arrests this type of yeast cell in G2 phase of the cell cycle
[36], whereas the block to proliferation in S. cerevisiae cells
is less clear.
Infection of terminally differentiated cells
Infection of T cells by HIV-1 requires cell activation and
exit from the quiescent, G0 stage of the cell cycle [37–39].
However, HIV-1 can also infect terminally differentiated
and other metabolically active nondividing cells [40–42].
This ability of HIV-1 to infect terminally differentiated
cells seems unusual, because it has long been known that
oncoviruses cannot integrate into the genomes of non-
proliferating cells [43,44]. Passage of cells through mitosis
is necessary for productive infection by oncoviruses
because entry of their proviral DNA into the nucleus
occurs only during mitosis [45,46]. 
Although one study argues that HIV-1 infects only prolif-
erating macrophages [47], others have shown that some
strains of HIV-1 replicate in terminally differentiated
macrophages and in stimulated peripheral blood lympho-
cytes with similar kinetics [48]. It is unlikely, therefore,
that efficient growth of HIV-1 in macrophages can be
explained by proliferation of a minor population of cells in
the macrophage cultures. Furthermore, HIV, but not
oncogenic retroviruses, can efficiently infect cells that are
artificially arrested in the cell cycle [42,46]. Lastly,
pseudotyped retroviral vectors made from HIV-1 can
infect neurons and astrocytes in rat brains — cell types
that do not divide and therefore cannot be infected with
oncoviral vectors [49].
The ability of HIV-1 to infect nondividing cells is presum-
ably related to the ability of the HIV-1 preintegration
complex to enter the nucleus of host cells during inter-
phase (reviewed in [50]). The preintegration complex is
defined as the RNA–protein complex in infected target
cells that is competent to integrate into the host genome
(Fig. 3). There are at least two karyophilic proteins in the
HIV-1 preintegration complex — the MA protein [51,52],
and Vpr [53]. The MA in the preintegration complex that
enters the nucleus is a minor form of the protein that is
phosphorylated on serines and/or the carboxy-terminal
tyrosine residue [54,55]. There appear to be two distinct
mechanisms by which HIV-1 can enter into the nucleus
(Fig. 3). An importin-dependent pathway is partially
mediated by the MA protein, and an importin-indepen-
dent pathway is mediated by Vpr [56]. These two inde-
pendent nuclear-entry pathways (Fig. 3) explain why Vpr
is functionally redundant with MA in allowing HIV-1
infection of nondividing cells [53,56].
The finding that Vpr is important for infection of non-
dividing cells and macrophages by HIV-1 is well-docu-
mented [57–59]. However, some controversy surrounds
the mechanism. One recent report [49] showed that Vpr
expressed in trans would permit a mutant HIV-1 that
lacked the vpr gene and encoded a mutant MA protein to
infect nondividing cells, as one might expect if Vpr pro-
motes entry into the nucleus; but another [58] found that
Vpr failed to act in trans to assist macrophage infection.
The difference between these results is difficult to
explain, but might be due to differences in levels of
expression of Vpr or to different vpr alleles. In addition,
there may be other effects of Vpr on virus replication in
macrophages that are independent of nuclear entry. Given
the number of secondary effects that Vpr can have in T
cells, this would not be altogether surprising. 
The quantitative effects of mutations in the MA nuclear
localization sequence (NLS) and Vpr on virus growth in
macrophages can also be variable [60]. This is probably
explained, however, by the presence of at least one addi-
tional protein in the preintegration complex, besides MA
and Vpr, which works better in some systems than in
others to mediate nuclear entry [49,56]. Adaptation to
growth in a variety of conditions may have selected for
multiple redundant mechanisms of nuclear entry. The
extent to which these different mechanisms are important
in various nondividing cell types has yet to be explored. 
Vpr localization in host cells
Vpr segregates into two compartments in virally infected
cells: it is efficiently and specifically incorporated into
virions by a process that is dependent on the p6 domain at
the carboxyl terminus of the Gag precursor polyprotein
[61–64], and it also accumulates in the nucleus [65,66]. It
is not clear how Vpr itself gets into the nucleus, or how it
influences entry of the preintegration complex. Vpr has no
amino-acid motif that resembles a typical NLS, but two
regions of the protein that are predicted to form amphi-
pathic a helices appear to be important for accumulation
of the protein in the nucleus [66,67]. Vpr enters the
nucleus by a different mechanism than the importin-
dependent pathway, because it is not blocked by a
dominant-negative mutant of importin-a, which docks
other NLS-containing proteins to the nuclear pore
complex; nuclear entry of Vpr is also not competed by an
excess of NLS-containing peptides [56]. 
Although the Vpr monomer is small enough to diffuse into
the nucleus passively, Vpr forms oligomers that probably
would not [68]. Vpr itself does not target reporter proteins
such as b-galactosidase into the nucleus when introduced
into cells as fusion proteins [67]; however, our recent data
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suggest that Vpr can target b-galactosidase to the nuclear
membrane (my group’s unpublished data). It is possible,
therefore, that Vpr-mediated entry of the preintegration
complex into the nucleus bypasses the need for importin
by either directly or indirectly linking the preintegration
complex to the nuclear membrane, whereupon other
mechanisms mediate its entry through the pore (Fig. 3).
Other Vpr-binding proteins, such as UNG, might then be
responsible for retaining Vpr in the nucleus. A novel
mechanism of nuclear entry has also been described for
U2 snRNP [69]. 
How does cell-cycle arrest aid viral replication?
It is not clear why HIV-1 encodes a protein that prevents
its host cells from proliferation. Many other viruses either
increase the proliferation of their host cells or prevent
their cell-cycle arrest by interfering with checkpoint
control [70–72]. Experiments with the SCID–Hu mouse
model, in which HIV-1-infected thymocytes are
implanted into a genetically immunocompromised mouse,
have failed to define a role for Vpr [73]. However, this
model differs from HIV-1 infection of humans in the pro-
liferative status of the infected cells and in the absence of
an immune response to the infection, which may be
important for Vpr to have an effect (see below). On the
other hand, viruses such as HIV-1 that mutate and repli-
cate rapidly evolve quickly, so that changes in the viral
genome that increase fitness only minimally are rapidly
fixed in the population, whereas slight replicative dis-
advantages are rapidly selected against [74,75]. It is there-
fore very unlikely that cell-cycle arrest by Vpr would be
maintained if it were not beneficial to virus replication.
The fact that the ability to cause G2 arrest is conserved
among diverse species of lentiviruses [76] also argues that
it must give some selective advantage.
Several hypotheses might explain how prevention of cell
proliferation could benefit virus growth. First, Vpr’s ability
to cause cell-cycle arrest in G2 may be required for it to
allow infection of nondividing cells. This is unlikely,
however, because these two functions are segregated into
separate proteins, Vpr and Vpx (Fig. 1), in the simian
immunodeficiency viruses (SIV) and HIV-2. The vpx
genes of SIV and HIV-2 have no role in cell-cycle arrest,
but are required for efficient infection of terminally differ-
entiated macrophages, whereas the vpr gene causes cells
to accumulate in G2 but has no role in infection of
macrophages [18,67,76–79]. The ability of Vpx to allow
SIV infection of nondividing cells is related to its ability to
allow the preintegration complex to enter the nucleus [79].
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The HIV-1 preintegration complex and nuclear entry. MA protein, Vpr,
nucleocapsid protein, integrase and reverse transcriptase are inside the
core with the viral RNA. After entry into cells, the viral core comes apart
(uncoating), and the preintegration complex enters the nucleus by either
an importin-dependent process mediated by MA protein — and another,
as yet unidentified viral protein — or an importin-independent process
mediated by Vpr. The stoichiometry of proteins in the preintegration
complex is not known. Reverse transcription is initiated but may not be
complete by the time that nuclear import occurs, and it is not known if the
components of the preintegration complex change during this process.
Because the ability to infect nondividing cells, and the
ability to cause cell-cycle arrest in G2 are unlinked in SIV
and HIV-2, they are probably are also unlinked in HIV-1.
Another hypothesis to explain a selection for Vpr-induced
G2 arrest is based on the observation that cytotoxic T lym-
phocyte (CTL)-induced apoptosis is dependent on pre-
mature activation of the mitotic Cdk [80]. When activation
of the cyclin B–p34cdc2 kinase is prevented by overexpres-
sion of wee1 (Fig. 2), cells are relatively protected from
apoptosis mediated by granzyme B, a protease secreted
from CTLs [81]. Because Vpr also prevents activation of
the cyclin B–p34cdc2 kinase, it is possible that Vpr has
evolved to prevent activation of the mitotic Cdk in order
to prolong the life span of HIV-infected cells in face of the
large CTL response in vivo. This hypothesis might help
explain why HIV-1 infection is persistent and cannot be
cleared by a seemingly robust CTL response [82]. 
A separate, but not mutually exclusive, hypothesis is that
the selection for Vpr is to maintain infected cells in G2,
because expression of viral genes is highest in this phase
of the cell cycle. Because infected cells have an average
life span of only 2.2 days [8], it may be better for the virus
to block the cells in a stage of the cell cycle when expres-
sion of viral genes is maximal. For example, we find that
both virus production and expression of viral RNA are
increased in G2 phase relative to G1 phase (my group’s
unpublished data). Any hypothesis to explain the func-
tional significance of cell cycle arrest in HIV-1 infection
must take into account the selective pressure for growth in
the face of rapid elimination of infected cells in vivo [7–9].
Viral manipulation of the cell cycle might be one way to
maximize viral expression in the brief time that virally
infected cells survive. 
Either of the hypotheses described above would be con-
sistent with data from studies of SIV-infected macaques
that show that deletion of vpr attenuates, but does not
abolish, viral pathogenicity [83,84]. That is, vpr gives the
virus an incremental selective advantage in overall growth,
but is not absolutely required for either virus growth or
pathogenicity. Deletion of both vpr and vpx in SIV,
however, virtually eliminates virus replication in animals
[80]. The Vpr protein of HIV-1, which combines the func-
tions of the SIV proteins Vpr and Vpx (Fig. 1), may thus
be crucial to viral replication in humans.
Future studies should concentrate on the major questions
of how and why HIV-1 affects the cell cycle, and how cell-
cycle arrest influences the viability of infected cells and
virus production. An understanding of how HIV-1 infects
nondividing cells may lead to a new generation of vectors
for gene therapy. Furthermore, an understanding of the
roles of Vpr in cell-cycle control and in the pathogenesis of
AIDS may ultimately aid the design of antiviral therapies
based on inhibition of Vpr function, and novel strategies
to inhibit the proliferation of tumor cells.
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